Therefore, it presents a new research direction in the area of GC treatment to detect whether FTO is related to the treatment of HER2-positive GC in the two signaling pathways of FTO-HOXB13-PI3K-AKT-mTOR and FTO-ITGB1-p-FAK (104, 108). This evidence concerns the gene MTOR and gastric cancer.